Prelude Therapeutics INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Soleus Capital Management L.P. and affiliated entities report beneficial ownership of 5.2% of Prelude Therapeutics Inc. common stock as of April 21, 2026.
NASDAQ
RA Capital Management and associated parties have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Prelude Therapeutics Incorporated.
NASDAQ
Krishna Vaddi, a key insider, has reported a beneficial ownership of 13.15% in Prelude Therapeutics Inc., totaling 6,745,647 shares.
NASDAQ
Incyte Corporation has reported a 9.9% beneficial ownership stake in Prelude Therapeutics, Inc., primarily through convertible non-voting common stock.
NASDAQ
SCHEDULE 13G/A: Prelude Therapeutics Insider Krishna Vaddi Discloses 13.8% Beneficial Ownership Stake
Krishna Vaddi, a key individual associated with Prelude Therapeutics Inc., has filed an amended Schedule 13G, disclosing a beneficial ownership of 13.8% of the company's common stock as of March 31, 2025.
NASDAQ
Krishna Vaddi, an individual, has reported a 9.5% beneficial ownership stake in Prelude Therapeutics Inc., totaling 5,489,130 shares as of December 31, 2024.
NASDAQ
Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn have reported a complete divestment of their beneficial ownership in Prelude Therapeutics Incorporated, now holding 0% of the common stock.